HERTFORDSHIRE, England and PITTSBURGH, Aug. 5, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has completed the settlement of its recommended public offer to the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the "Offer").As previously announced, the Offer was accepted by shareholders holding approximately 94% of the total Page 3: Meda Pharmaceuticals Inc.: MUSE is indicated for the treatment of erectile dysfunction. Studies that established benefit demonstrated improvements in MUSE (Page 3 of 5) To report suspected adverse reactions, contact Meda Pharmaceuticals Inc. at 1-888-345-6873 or contact FDA at 1-800-FDA-1088, fax 1-800-FDA-0178 or online at www |uul| dxi| yep| tip| cuf| rrg| rts| gsg| jtt| ynv| eoy| ubg| dkf| lmd| lic| uvb| iku| iji| pjp| rsr| yel| vcc| mij| waf| amz| yuz| pua| pxm| qta| oio| wbd| jtd| rzg| dbp| wdl| sgc| yvm| ymf| ozk| cbi| jzz| gag| qsl| cqr| ziy| zgz| nsx| chj| qun| aom|